-
Hefei Research Institute has developed a new type of tropomyosin receptor kinase inhibitor
Time of Update: 2022-06-22
NTRK gene fusion occurs in a variety of solid tumors in adults and children, including breast cancer, colorectal cancer, non-small cell lung cancer, and various sarcomas .
-
Express plans to spend about $1.9 billion to harvest Phase 3 clinical JAK inhibitors, GlaxoSmithKline expands hematology pipeline
Time of Update: 2022-06-17
Sierra Oncology's innovative JAK inhibitor momelotinib recently met all primary and key secondary endpoints in a pivotal Phase 3 clinical trial in patients with myelofibrosis and is expected to submit a regulatory filing in the U.
-
KRAS G12C Inhibitors: From Single Drug Competition to Combination Therapy Breakthrough
Time of Update: 2022-06-16
Amgen announced two years of long-term follow-up data on sotorasib in KRAS G12C-mutated non-small cell patients .
-
@Tonic patient, the first domestic oral JAK inhibitor approved for indications!
Time of Update: 2022-06-14
that China's National Medical Products Administration (NMPA) has approved citric acid Tofacitinib (trade name: Shangjie) is indicated for adult patients with active ankylosing spondylitis (AS) for whom one or more TNF blockers are insufficiently
-
Pfizer's third-generation ALK inhibitor lorlatinib approved in China for the treatment of non-small cell lung cancer
Time of Update: 2022-05-29
On April 29, the NMPA official website announced that Pfizer’s lorlatinib tablets have been approved in China for the treatment of ALK-positive locally advanced or metastatic non-small cell
-
AbbVie's JAK inhibitor "Upatinib Sustained-Release Tablets" is expected to be approved in China in the near future
Time of Update: 2022-05-29
It is hoped that AbbVie Upatinib Sustained-Release Tablets will be approved in China as soon as possible, which will provide new treatment options for Chinese patients with atopic dermatitis!References:[1] Drug registration progress query on NMPA official website.
-
Following the "Y Drug", the second CTLA-4 inhibitor will be approved soon, and the race to upgrade the track begins
Time of Update: 2022-05-29
Today, let's sort out the mechanism of action and research and development direction of CTLA-4 inhibitor, the world's first approved immune checkpoint inhibitor.
-
Qilu Ruige CDK2/4/6 inhibitor RGT-419B was reported for the first time in China
Time of Update: 2022-05-29
The clinical development program for RGT-419B will address this resistance to CDK4/6 and other hormone receptor modulating therapies, providing new opportunities to improve survival and quality of life for patients with advanced breast cancer .
-
Bayer's Kerendia gets EU approval to compete with AZ and Eli Lilly's SGLT-2 inhibitors
Time of Update: 2022-05-28
Compilenewborn>Recently, Bayer's new kidney disease drug Kerendia (finerenone, feneridone, 10mg or 20mg) was approved in the European Union, the drug
-
Upstart BTK inhibitor sells at least $11 billion globally in 2021
Time of Update: 2022-05-28
Globally Approved BTK Inhibitors(Source: CITIC Securities Research)Sales of major BTK inhibitors have continued to grow since their launch .
-
Bayer withdraws PI3K inhibitor application for one indication
Time of Update: 2022-05-28
Bayer submitted the first domestic application for the product in March 2021 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two systemic therapies in the past.
-
The symptoms of nearly half of the express patients improved by at least 40%, and AbbVie's JAK inhibitor was approved by the FDA
Time of Update: 2022-05-28
S. FDA approved the expanded indication of its JAK inhibitor Rinvoq (upadacitinib, upadacitinib) for the treatment of active ankylosing spondylitis (ankylosing spondylitis, AS) adult patients .
-
AbbVie Upatinib Approved in my country to Inventory 8 Iteratively Marketed JAK Inhibitors Worldwide
Time of Update: 2022-05-28
Text by Bu Yuan>On February 24, the official website of China's National Medical Products Administration (NMPA) showed that AbbVie's JAK inhibitor upadatinib
-
PD-L1 inhibitor combination has been granted priority review by the FDA
Time of Update: 2022-05-27
” Reference: [1] Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial.
-
Interim Analysis Shows Positive Efficacy SGLT2 Inhibitor Early Termination of Phase 3 Clinical Trial
Time of Update: 2022-05-27
On March 17, Eli Lilly and Company and Boehringer Ingelheim jointly announced that the SGLT2 inhibitor empagliflozin for the treatment of chronic kidney disease (CKD) patients was based on the recommendation of an independent data monitoring committee.
-
-term clinical results of Novartis CDK4/6 inhibitor are positive
Time of Update: 2022-05-27
▎WuXi AppTec Content Team Editor Today, Novartis announced that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant as first-line therapy in postmenopausal patients with HR+/HER2- advanced
-
Double progression-free survival with PARP inhibitor as first-line maintenance therapy for ovarian cancer
Time of Update: 2022-05-26
References:[1] Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial.
-
Vertex's ion channel inhibitor receives Phase 2 clinical proof of concept
Time of Update: 2022-05-26
References:[1] Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain.
-
Junjing Bio's fourth-generation EGFR inhibitor applied for clinical application
Time of Update: 2022-05-26
At present, domestic companies developing fourth-generation EGFR inhibitors include Betta Pharmaceuticals, Zai Lab, Chia Tai Tianqing, Hongyun Bio, Qilu Pharmaceutical, and Jinan University .
-
AbbVie's JAK Inhibitor "Upatinib" Approved in China for the Third Indication
Time of Update: 2022-05-25
upadatinib extended-release tablets was approved for the treatment of active patients with poor efficacy or intolerance to one or more DMARDs. Psoriatic arthritis (PsA) in adults . >
